In conclusion, our results suggest that the novel but rare variant of TP53 is not associated with risk of melanoma, which is similar to the finding of a meta-analysis including 19,423 cancer patients and 54,050 controls; nor a risk association for lung cancer but a possible protection against SCCHN. This evidence concerns the gene TP53 and cancer.